Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Apr 1;76(7):1935-41.
doi: 10.1158/0008-5472.CAN-15-2406. Epub 2016 Feb 26.

Low Levels of Circulating Adiponectin Are Associated with Multiple Myeloma Risk in Overweight and Obese Individuals

Jonathan N Hofmann  1 , Brenda M Birmann  2 , Lauren R Teras  3 , Ruth M Pfeiffer  4 , Ye Wang  5 , Demetrius Albanes  4 , Dalsu Baris  4 , Graham A Colditz  6 , Anneclaire J De Roos  7 , Graham G Giles  8 , H Dean Hosgood  9 , Qing Lan  4 , Ola Landgren  10 , Linda M Liao  4 , Nathaniel Rothman  4 , Stephanie J Weinstein  4 , Michael N Pollak  5 , Marian L Neuhouser  11 , Mark P Purdue  4
Affiliations

Low Levels of Circulating Adiponectin Are Associated with Multiple Myeloma Risk in Overweight and Obese Individuals

Jonathan N Hofmann et al. Cancer Res. .

Abstract

The association between obesity and multiple myeloma risk may be partly attributed to reduced circulating levels of adiponectin in obese individuals. To prospectively evaluate multiple myeloma risk in relation to adiponectin levels overall and stratified by body mass index and other characteristics, we conducted a pooled investigation of pre-diagnosed peripheral blood samples from 624 multiple myeloma cases and 1,246 individually matched controls from seven cohorts participating in the Multiple Myeloma Cohort Consortium. Analysis of circulating analyte levels measured by ELISA revealed that higher total adiponectin levels were associated with reduced multiple myeloma risk overall [highest quartile vs. lowest: OR, 0.64; 95% confidence interval (CI) 0.47-0.85; Ptrend = 0.001]. This association was apparent among cases diagnosed six or more years after blood collection (OR, 0.60; 95% CI, 0.40-0.90; Ptrend = 0.004) and was similar in magnitude for men and women (OR, 0.59 and 0.66, respectively). Interestingly, we observed strong associations among subjects who were overweight (OR, 0.41; 95% CI, 0.26-0.65) or obese (OR, 0.41; 95% CI, 0.17-0.98) but not among those with normal weight (OR, 1.20; 95% CI, 0.73-2.00; overweight/obese vs. normal weight, Pinteraction = 0.04). Our findings provide the strongest epidemiologic evidence to date that adiponectin protects against multiple myeloma development, particularly among overweight and obese individuals, and offer a method for risk assessment in this susceptible population of heavier patients. Cancer Res; 76(7); 1935-41. ©2016 AACR.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest: None declared

Figures

Figure 1
Figure 1
Risk of MM in relation to circulating total adiponectin levels estimated using restricted cubic spline regression models with 4 knots, among individuals with A) body mass index (BMI) <25 kg/m2 (P-linear = 0.8, P-nonlinearity = 0.8); and B) BMI ≥25 kg/m2 (P-linear = 0.0001, P-nonlinearity = 0.4). The odds ratio is represented by the solid line, and the 95% confidence interval (CI) is represented by the shaded area.
Figure 2
Figure 2
Cohort-specific and meta-analysis summary odds ratios (OR) and 95% confidence intervals (CI) for the relationship between circulating total adiponectin levels (above vs. below median) and risk of MM.
See this image and copyright information in PMC

References

    1. ACS. Cancer Facts & Figures 2015. Atlanta, GA: American Cancer Society; 2015.
    1. Baris D, Brown LM, Andreotti G, Devesa SS. Epidemiology of Multiple Myeloma. In: Wiernik PH, Goldman JM, Dutcher JP, Kyle RA, editors. Neoplastic Diseases of the Blood. Fifth Edition. New York: Springer; 2013. pp. 547–563.
    1. De Roos AJ, Baris D, Weiss NS, Herrinton LJ. Multiple Myeloma. In: Schottenfeld D, Fraumeni JF, editors. Cancer Epidemiology and Prevention. Third Edition. New York: Oxford University Press; 2006. pp. 919–945.
    1. Hofmann JN, Moore SC, Lim U, et al. Body mass index and physical activity at different ages and risk of multiple myeloma in the NIH-AARP diet and health study. Am J Epidemiol. 2013;177(8):776–786. - PMC - PubMed
    1. Teras LR, Kitahara CM, Birmann BM, et al. Body size and multiple myeloma mortality: a pooled analysis of 20 prospective studies. Br J Haematol. 2014;166(5):667–676. - PMC - PubMed

Publication types